Compare SCOR & AARD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SCOR | AARD |
|---|---|---|
| Founded | 1999 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 101.6M | 107.7M |
| IPO Year | 2007 | 2025 |
| Metric | SCOR | AARD |
|---|---|---|
| Price | $4.89 | $5.06 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $15.29 |
| AVG Volume (30 Days) | 44.4K | ★ 132.0K |
| Earning Date | 05-05-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 127.37 | 43.11 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $403,549,000.00 | N/A |
| Revenue This Year | $2.75 | N/A |
| Revenue Next Year | $7.30 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 1.02 | N/A |
| 52 Week Low | $4.60 | $3.35 |
| 52 Week High | $10.18 | $17.94 |
| Indicator | SCOR | AARD |
|---|---|---|
| Relative Strength Index (RSI) | 40.06 | 45.27 |
| Support Level | $4.60 | $4.99 |
| Resistance Level | $7.72 | $6.01 |
| Average True Range (ATR) | 0.39 | 0.69 |
| MACD | 0.06 | -0.12 |
| Stochastic Oscillator | 42.76 | 36.46 |
comScore Inc is a information and analytics company that measures advertising, content, and the consumer audiences of each, across media platforms. It create products using a data platform that combines information on digital platforms (connected televisions, mobile devices, tablets and computers), televisions, direct to consumer applications, and movie screens with demographics and other descriptive information. The company has developed proprietary data science that enables measurement of person-level and household-level audiences, removing duplicated viewing across devices and over time. Its segments include Content & Ad Measurement and Research & Insight Solutions of which the Content & Ad Measurement segment derives the majority of the revenue.
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.